Ferinject Adverse Reactions

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Full Prescribing Info

Adverse Reactions

Adverse drug reactions reported in subjects (n> 8,000) from clinical trials as well as those reported from the post-marketing experience are summarised in the table as follows.
The most commonly reported ADR is nausea, occurring in 2.9% of the subjects, followed by injection/infusion site reactions, hypophosphataemia, headache, flushing, dizziness and hypertension. Injection/infusion site reactions comprise several ADRs which individually are either uncommon or rare.
For subjects in clinical trials that showed a decrease in serum phosphorous, the minimum values were obtained after approximately 2 weeks, and in most cases returned to baseline values by 12 weeks following Ferinject treatment. The most serious ADR is anaphylactoid/anaphylactic reactions (rare); fatalities have been reported. See Precautions for further details. (See Table 4.)

Click on icon to see table/diagram/image

View ADR Reporting Link

Ferinject Adverse Reactions

ferric carboxymaltose

Manufacturer:

Vifor Pharma

Distributor:

Zuellig Pharma